ConductScience.org, home

Paper18820

Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients.

Tutschka PJ and 1 other. Transplantation, 1977. Cited by 78 papers, by iCite.

Cite this record

ConductScience Library. Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients. Papers, record 18820. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18820

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients.
PubMed
Journal
Transplantation
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
78
iCite
Relative citation ratio, by iCite
2.41
iCite
Revised in PubMed
2021-12-03
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tutschka PJP J
2Santon GWG W

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bone Marrow CellsMajor topic
Bone Marrow TransplantationMajor topic
BusulfanMajor topic
Immunosuppression TherapyMajor topic
Animals
Antilymphocyte Serum
Cyclophosphamide
Dose-Response Relationship, Immunologic
Female
Graft vs Host Reaction
Kinetics
Rabbits
Rats
Rats, Inbred ACI
Rats, Inbred Lew
T-Lymphocytes
Transplantation, Homologous

Source PubMed

Download CSV of topics

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 78 citations.

PMIDTitleJournalYearIn PapersSource
31763350Immunoresponse to Gene-Modified Hematopoietic Stem Cells.Mol Ther Methods Clin Dev2020https://conductscience.org/library/papers/31763350PubMed
31253582Busulfan Combined with Immunosuppression Allows Efficient Engraftment of Gene-Modified Cells in a Rhesus Macaque Model.Mol Ther2019https://conductscience.org/library/papers/31253582PubMed
25066812Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome.J Thromb Haemost2014https://conductscience.org/library/papers/25066812PubMed
20305698Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.Bone Marrow Transplant2011https://conductscience.org/library/papers/20305698PubMed
16543070Busulfan-conditioned bone marrow transplantation results in high-level allogeneic chimerism in mice made tolerant by in utero hematopoietic cell transplantation.Exp Hematol2006https://conductscience.org/library/papers/16543070PubMed
14578930Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection.Bone Marrow Transplant2004https://conductscience.org/library/papers/14578930PubMed
12774057A rat model of syngeneic bone marrow transplantation during breast cancer therapy.Bone Marrow Transplant2003https://conductscience.org/library/papers/12774057PubMed
12189535Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.Bone Marrow Transplant2002https://conductscience.org/library/papers/12189535PubMed
11041565Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.Bone Marrow Transplant2000https://conductscience.org/library/papers/11041565PubMed
10800058An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.Bone Marrow Transplant2000https://conductscience.org/library/papers/10800058PubMed
10070870Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.Br J Cancer1999https://conductscience.org/library/papers/10070870PubMed
6377541Preparation for bone marrow transplantation.Springer Semin Immunopathol1984https://conductscience.org/library/papers/6377541PubMed
2487253Immunomagnetic T-lymphocyte depletion (ITLD) of rat bone marrow using OX-19 monoclonal antibody.J Invest Surg1989https://conductscience.org/library/papers/2487253PubMed
2122122Displacement bone marrow transplantation for some inborn errors.J Inherit Metab Dis1990https://conductscience.org/library/papers/2122122PubMed
45208Use of cyclosporin A in allogeneic bone marrow transplantation in the rat.Nature1979https://conductscience.org/library/papers/45208PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/18820

GET https://conductscience.org/api/papers/v1/18820/authors